회사 개요
Catalyst Pharmaceuticals, Inc. (CPRX) operates as a commercial-stage biopharmaceutical entity dedicated to the development and commercialization of therapeutic medicines for patients affected by rare diseases within the United States. The company functions within the healthcare sector, specifically the biotechnology industry, where its focus is on addressing unmet medical needs through specialized pharmaceutical interventions. With a market capitalization of $3.15B, an annual revenue of $588.99M, and a workforce of 182 employees, the firm has established a significant presence in the niche market for rare disease treatments. These valuation and revenue figures indicate that the company has moved beyond early-stage research to a phase where it is actively generating substantial commercial returns while maintaining a lean operational structure typical of specialized biotechnology firms.
재무 건전성
Catalyst Pharmaceuticals reported a revenue of $588.99M and a net income of $214.33M over the trailing twelve months, with an EBITDA of $295.65M. The substantial gap between the $588.99M in revenue and the $214.33M in net income reveals a highly efficient cost structure where operating expenses and taxes consume approximately 63.6% of total revenue, yet still leave a robust profit margin. The company generated $171.34M in free cash flow, which provides significant financial flexibility to fund future R&D initiatives, manage working capital, or pursue strategic acquisitions without relying heavily on external financing. The company maintains a gross margin of 83.0%, an operating margin of 40.5%, and a profit margin of 36.4%, all of which indicate strong pricing power and high efficiency in converting sales into earnings typical of the biotechnology sector. On the balance sheet, Catalyst holds $709.17M in cash against minimal debt of $2.79M, resulting in a debt-to-equity ratio of 0.29, which demonstrates a highly conservative and low-leveraged financial position. A current ratio of 6.08 further confirms exceptional short-term liquidity, suggesting the company possesses more than six times the current assets necessary to cover its short-term liabilities. Additionally, the return on equity stands at 25.5% while the return on assets is 16.5%, metrics that reveal management's effectiveness in generating high returns on the capital invested in the business relative to its equity base and total asset utilization.
밸류에이션 평가
The trailing twelve-month P/E ratio is 15.24, while the forward P/E is projected at 8.22, implying that the market expects a significant expansion in earnings per share over the coming year. The price-to-book ratio of 3.29 suggests that the market is valuing the company at more than three times its book value, reflecting a premium assigned to its intangible assets, proprietary drug pipelines, and growth potential. Alternative valuation metrics such as a price-to-sales ratio of 5.34 and an EV/EBITDA of 8.19 provide further context, indicating that the company trades at a premium relative to its sales and earnings power compared to traditional industrial peers. The stock has traded between a 52-week low of $19.05 and a 52-week high of $26.58, and depending on the specific trading price, the current valuation sits within this historical range, reflecting market sentiment regarding its growth prospects. With a beta of 0.66, the stock exhibits lower volatility than the broader market, suggesting that its price movements are less sensitive to general market fluctuations compared to the average large-cap stock.
Growth & Income
Catalyst Pharmaceuticals achieved a revenue growth rate of 7.6% year-over-year, whereas earnings growth for the same period was -6.4%, indicating that earnings are currently growing slower than revenue due to the one-time impact of the previously reported net income figures. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means all earnings are retained and reinvested into the company's growth initiatives rather than being distributed to shareholders. This reinvestment strategy is characteristic of growth-oriented biotechnology companies that prioritize expanding their product portfolios and research programs over providing immediate income to investors. Overall, the company presents a profile characterized by strong revenue expansion, high profitability margins, and a capital allocation strategy focused on internal growth rather than dividend income.